Clinical characteristics of the 222 patients with diffuse large B-cell lymphoma according to survivin expression
| Characteristic . | Survivin negative . | Survivin positive . | P . |
|---|---|---|---|
| No. of patients (%) | 88 (40) | 134 (60) | |
| Age (%) | .56 | ||
| No older than 60 y | 56 (64) | 80 (60) | |
| Older than 60 y | 32 (36) | 54 (40) | |
| Histologic subtype (%) | .10 | ||
| Centroblastic | 81 (92) | 130 (97) | |
| Immunoblastic | 7 (8) | 4 (3) | |
| Clinical stage (%) | .12 | ||
| I or II | 45 (52) | 54 (41) | |
| III or IV | 42 (48) | 78 (59) | |
| Bulky disease > 10 cm (%) | .31 | ||
| No | 43 (52) | 76 (59) | |
| Yes | 40 (48) | 53 (41) | |
| Bone marrow involvement (%) | .11 | ||
| No | 71 (90) | 103 (82) | |
| Yes | 8 (10) | 23 (18) | |
| Extranodal sites (%) | .91 | ||
| 0-1 site | 63 (72) | 95 (71) | |
| More than 1 site | 25 (28) | 39 (29) | |
| Performance status (%) | .07 | ||
| 0-1 | 69 (83) | 95 (73) | |
| More than 1 | 14 (17) | 36 (27) | |
| Lactate dehydrogenase (%) | 0.99 | ||
| Normal | 33 (40) | 48 (40) | |
| Elevated | 50 (60) | 73 (60) | |
| IPI Score (%) | 0.48 | ||
| 0-1 | 37 (46) | 45 (38) | |
| 2 | 17 (21) | 26 (22) | |
| 3 | 17 (21) | 24 (20) | |
| 4-5 | 10 (12) | 24 (20) | |
| Treatment (%) | 0.72 | ||
| ACVB | 30 (34) | 49 (36) | |
| m-BACOD (group 1) | 18 (21) | 20 (15) | |
| NCVB (group 2) | 16 (18) | 20 (15) | |
| VIM3 (group 3) | 15 (17) | 29 (22) | |
| CTVP (group 4) | 9 (11) | 16 (12) | |
| Evolution (%) | 0.29 | ||
| Complete remission | 57 (68) | 74 (61) | |
| No complete remission | 27 (32) | 48 (39) |
| Characteristic . | Survivin negative . | Survivin positive . | P . |
|---|---|---|---|
| No. of patients (%) | 88 (40) | 134 (60) | |
| Age (%) | .56 | ||
| No older than 60 y | 56 (64) | 80 (60) | |
| Older than 60 y | 32 (36) | 54 (40) | |
| Histologic subtype (%) | .10 | ||
| Centroblastic | 81 (92) | 130 (97) | |
| Immunoblastic | 7 (8) | 4 (3) | |
| Clinical stage (%) | .12 | ||
| I or II | 45 (52) | 54 (41) | |
| III or IV | 42 (48) | 78 (59) | |
| Bulky disease > 10 cm (%) | .31 | ||
| No | 43 (52) | 76 (59) | |
| Yes | 40 (48) | 53 (41) | |
| Bone marrow involvement (%) | .11 | ||
| No | 71 (90) | 103 (82) | |
| Yes | 8 (10) | 23 (18) | |
| Extranodal sites (%) | .91 | ||
| 0-1 site | 63 (72) | 95 (71) | |
| More than 1 site | 25 (28) | 39 (29) | |
| Performance status (%) | .07 | ||
| 0-1 | 69 (83) | 95 (73) | |
| More than 1 | 14 (17) | 36 (27) | |
| Lactate dehydrogenase (%) | 0.99 | ||
| Normal | 33 (40) | 48 (40) | |
| Elevated | 50 (60) | 73 (60) | |
| IPI Score (%) | 0.48 | ||
| 0-1 | 37 (46) | 45 (38) | |
| 2 | 17 (21) | 26 (22) | |
| 3 | 17 (21) | 24 (20) | |
| 4-5 | 10 (12) | 24 (20) | |
| Treatment (%) | 0.72 | ||
| ACVB | 30 (34) | 49 (36) | |
| m-BACOD (group 1) | 18 (21) | 20 (15) | |
| NCVB (group 2) | 16 (18) | 20 (15) | |
| VIM3 (group 3) | 15 (17) | 29 (22) | |
| CTVP (group 4) | 9 (11) | 16 (12) | |
| Evolution (%) | 0.29 | ||
| Complete remission | 57 (68) | 74 (61) | |
| No complete remission | 27 (32) | 48 (39) |